Fezolinetant Safe, Effective for Moderate-to-Severe Menopause Hot Flashes
By Lori Solomon HealthDay Reporter
MONDAY, May 20, 2024 -- Fezolinetant is safe and effective for moderate-to-severe vasomotor symptoms (VMS), according to a study presented at the annual European Congress of Endocrinology, hosted by the European Society of Endocrinology from May 11 to 14 in Stockholm.
Angelica Lindén Hirschberg, M.D., Ph.D., from the Karolinska Institutet in Stockholm, and colleagues assessed early response to fezolinetant in terms of frequency and severity of moderate-to-severe VMS. The analysis included 453 women unsuitable for hormone therapy participating in the 24-week placebo-controlled DAYLIGHT study.
The researchers found that compared with those taking placebo, participants treated with fezolinetant (45 mg) had a greater reduction in the daily mean change in frequency of moderate-to-severe VMS from baseline through the first week of treatment (day 7 least squares mean difference, –2.20). There was a decrease observed in VMS frequency from days 1 to 6, with the strongest decrease seen during the first three days. Additionally, fezolinetant was associated with greater reduction in the daily mean change in VMS severity from days 2 to 7 compared with placebo (day 7 least squares mean difference, –0.17). Through week 24, improvements in VMS frequency and severity were sustained. There were no safety signals of concern reported through week 24.
"An effect on VMS frequency was seen as early as day 1 and maintained through the 24-week placebo-controlled period, demonstrating a rapid onset of action and sustained efficacy with fezolinetant treatment," the authors write.
The study was funded by Astellas Pharma, the manufacturer of fezolinetant.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted May 2024
Read this next
Survey Reveals Women May Be Experiencing Perimenopause in Their 40s
FRIDAY, April 25, 2025 -- Six in 10 women believe they will hit menopause in their 40s, according to survey results released April 8 by The Ohio State University Wexner Medical...
Common Photosensitizing Drugs Increase Skin Cancer Risk
TUESDAY, April 1, 2025 -- Some commonly prescribed photosensitizing drugs increase skin cancer risk, according to a study published online March 18 in Photodermatology...
Low Creatinine-to-Cystatin C Ratio Tied to Lower Muscle Volume in Midlife Women
MONDAY, March 31, 2025 -- Among middle-aged women, low creatinine-to-cystatin C ratio (CCR) at baseline is associated with lower fat-free muscle volumes and poorer gait speeds 6.6...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.